Euromed Pharma joins Pharma.Aero as a member of the Life Science Manufacturers Advisory Platform

Euromed Pharma signed up as a member of Pharma.Aero’s Life Sciences Manufacturers Advisory Platform, becoming LMAP’s 10th pharmaceutical manufacturer. With the latest additions, Pharma.Aero consolidates its position as a hub for industry collaboration and innovation.

Euromed Pharma’s extensive expertise in Advanced Therapy Medicinal Products (ATMP) clinical trials and product market access enriches the collective knowledge base of the Life Sciences Manufacturers Advisory Platform.

Frank Van Gelder, Secretary General of Pharma.Aero, welcomes Euromed Pharma to the global community: “We are excited to welcome Euromed Pharma to our platform, and look forward to leveraging their insights and contributions to drive positive change and accelerate the delivery of life-saving therapies around the globe.

Euromed Pharma is delighted to become a member of the global cross-industry collaboration platform, Pharma.Aero. As a manufacturer and supply chain expert in Life Science, we daily provide support to biotech, R&D and pharmaceutical companies to ensure the success of their clinical trials and product access to the market. Together, we navigate throughout the drug's lifecycle.

Olivier Mary, Chief Commercial & Supply Project Director Euromed Pharma

By signing up for the LMAP, Euromed Pharma joins a select group of industry leaders within the Life Sciences Manufacturers Advisory Platform: MSD, Pfizer, Zoetis, Novartis, Johnson & Johnson, Bayer, Astra Zeneca’s Alexion, GSK and Germinare.

Pharma.Aero created the Life Science Manufacturers Advisory Platform (LMAP) to further engage the manufacturing segment to provide first-line advice on the activities and projects of Pharma.Aero and support the logistics and supply chain industry. The LMAP integrates into all Pharma.Aero cross-industry initiatives and provide content value to the organization.


Back to overview
My cart
Your cart is empty.

Looks like you haven't made a choice yet.